TD Cowen upgraded PTC Therapeutics (PTCT) to Buy from Hold with a price target of $90, up from $75. The company’s 2026 product revenue guidance was raised on the back of Sephience sales, the analyst tells investors in a research note. TD says its key opinion leader checks indicate “continued strong momentum” for PTC’s phenylketonuria launch. The company is also well-funded with a stabilizing balance sheet, adds the firm.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year
- PTC Therapeutics raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M
- PTC Therapeutics Lifts 2026 Outlook on Sephience Momentum
- Tazeen Ahmad Reiterates Buy on Strengthened Votoplam Profile and Sephience Momentum; Keeps $93 Price Target Unchanged
- PTC Therapeutics Reports Positive 24-Month Votoplam Data